TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00806871
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution 0,9%, injection in the carpal tunnel, one time use~1 ml 10 mg Lidocaine + 2 ml saline
Study: NCT02894008
Drug: ChAd63-KH
Normalized name: KH-176
DrugBank: Sonlicromanol (DB16333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAd63-KH in adults and adolescents with persistent PKDL.
Study: NCT01322308
Drug: pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg tablet QD (taken once daily)
Study: NCT02000154
Drug: SyB L-1101
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SyB L-1101 (rigosertib sodium) will be administered intravenously 72 continuous hours (3 days), followed by 25-day observation period. The treatment period of 28 days (3 days of administration + 25 days of observation) constitutes 1 cycle. The dose at cycle 8 in the study 2011005 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 9). From cycle 10 on, the dose of SyB L-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle.
Study: NCT02374047
Drug: CAT-2054
Normalized name: Spotted cat
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02374047
Drug: CAT-2054-C
Normalized name: Spotted cat
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02374047
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01744912
Drug: Ublituximab
Normalized name: Ublituximab
DrugBank: Ublituximab (DB11850)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ublituximab is a novel monoclonal antibody targeting CD20
Study: NCT01744912
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide has both immunomodulatory and anti-angiogenic properties which could confer antitumor and antimetastatic effects
Study: NCT00057122
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mg
Study: NCT00057122
Drug: Rifapentine
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifapentine 900 mg
Study: NCT00057122
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg
Study: NCT00967928
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be administered intravenously once weekly at 40mg/m2 for 6 weeks. The preferred administration day is Monday.
Study: NCT01639508
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive cabozantinib at an initial dose of 60 mg orally daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. Dose modifications for drug toxicity are permitted as per a prescribed algorithm. During the Treatment Period subjects will receive cabozantinib until either disease progression, the occurrence of unacceptable drug-related toxicity or for other reason(s) for subject withdrawal.
Study: NCT03842228
Drug: Copanlisib Hydrochloride
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03842228
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00894374
Drug: Artesunate (Test)
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral tablet, single dose, 1 x 100 mg
Study: NCT00894374
Drug: Artesunate (Comparator)
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral tablet, single dose, 2 x 50 mg
Study: NCT00504582
Drug: Fibrin Sealant
Normalized name: FIBRIN SEALANT
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tisseel applied externally to the dissected axillary area.
Study: NCT03932201
Drug: Damoctocog alfa pegol (Jivi, Bay94-9027)
Normalized name: damoctocog alfa pegol
DrugBank: Damoctocog alfa pegol (DB14700)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow clinical practice. BAY94-9027 is a B-domain-deleted recombinant factor VIII (rFVIII) product site-specifically conjugated to a single (dual 30-kDa branched) 60-kDa polyethylene glycol (PEG) molecule. BAY 94-9027 is intended for prophylaxis and treatment of bleeds in patients with hemophilia A aged ≥12 years, with a narrow, predictable weekly dose that allows for the treatment regimen to be tailored to individual patient needs.
Study: NCT00817219
Drug: Calcipotriene plus betamethasone dipropionate ointment
Normalized name: betamethasone dipropionate / calcipotriene Topical Cream
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily application for 4 weeks
Study: NCT04048811
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The induction dose is 2.0mg/mg. The initial maintenance dose of the first 2 subject is 5 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 2 subjects, so as to explore the optimal initial maintenance dose. The adjustment range of the initial maintenance dose is 5 (± 2.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 2.5 mg/kg/h, and the maximum should not be more than 7.5 mg/kg/h.
Study: NCT04048811
Drug: Propofol HSK3486
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The induction dose of Propofol is 2.0mg/mgThe initial maintenance dose of HSK3486 is fixed at 1 mg/kg/h, without adjustment.
Study: NCT02927067
Drug: Maribavir
Normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive 400 mg of maribavir BID orally.
Study: NCT02927067
Drug: Valganciclovir
Normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive valganciclovir tablets orally.
Study: NCT01908738
Drug: paracervical block with 1%lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To determine effectiveness of paracervical block, lidocaine spray and only oral analgesic drugs for pain relief during endometrial biopsy.~Pain score(NRS) immediately after procedure and 15 minutes Group 1(1%Lidocaine) Group 2(10%Lidocaine spray) Control group(Placebo) Pain score immediately Pain score 15 minutes
Study: NCT01908738
Drug: 10%lidocaine spray
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03072771
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: -Blinatumomab is a bispecific T cell engaging antibody
Study: NCT03072771
Drug: Carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: -Carmustine is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of carmustine.
Study: NCT03072771
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: -Etoposide is a semi-synthetic podophyllotoxin derivative. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of etoposide.
Study: NCT03072771
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: -Cytarabine, commonly known as Ara-C, is a synthetic nucleoside. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of cytarabine.
Study: NCT03072771
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: -Melphalan is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of melphalan.
Study: NCT01445054
Drug: 111Indium CHX-A
Normalized name: 111Indium pentetreotide
DrugBank: Indium (DB11659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 111Indium CHX-A will be administered intravenously over a 10-15 minute period using an intravenous catheter
Study: NCT01520831
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
Study: NCT01520831
Drug: biphasic insulin aspart 50
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
Study: NCT01520831
Drug: biphasic insulin aspart 70
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
Study: NCT01520831
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
Study: NCT02934529
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan 180 mg/m² iv, 30 - 90 min., day 1, q d15
Study: NCT02934529
Drug: Folinic Acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1, q d15
Study: NCT02934529
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 400 mg/m² bolus day 1, q d15
Study: NCT02934529
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 2400 mg/m² iv over 46 h day 1-2, q d15
Study: NCT02934529
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) day 1 + 8
Study: NCT02934529
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 7.5 mg/kg BW iv over 30 to 90 minutes: day 1
Study: NCT02934529
Drug: regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 160 mg per day (day 1-21) (repeated on day 28)
Study: NCT02934529
Drug: Irinotecan 125mg
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan 125 mg/m² iv, 60 - 90 min. weekly (D1, D8, D15, D22)
Study: NCT02934529
Drug: Cetuximab wkly
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) weekly (D1, D8, D15, D22, D29, D36)
Study: NCT00944385
Drug: ulinastatin
Normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer 30000U/ulinastatin. Comparison of different dosages of drug.
Study: NCT00000203
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04074473
Drug: propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure\>90mmHg)
Study: NCT02044276
Drug: lipegfilgrastim
Normalized name: Lipegfilgrastim
DrugBank: Lipegfilgrastim (DB13200)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 6 mg
Study: NCT02044276
Drug: pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 mg
Study: NCT00812305
Drug: SKY0402 300mg in hepatically impaired patients
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in hepatically impaired patients
Study: NCT01540682
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: \~ 1 week prior to the initiation of radiation therapy and continuing for a grand total of 12 weeks.
Study: NCT02684318
Drug: PM01183 + olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02278471
Drug: Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)
Normalized name: POLYPILUS FRONDOSUS WHOLE
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01575288
Drug: High-dose trehalose
Normalized name: Trehalose
DrugBank: Trehalose (DB12310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100g 1/day
Study: NCT00083096
Drug: lonafarnib
Normalized name: LONAFARNIB
DrugBank: Lonafarnib (DB06448)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00083096
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03468543
Drug: Memantine Hydrochloride MR Prototype Capsule Formulation A
Normalized name: Memantine Hydrochloride
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Memantine HCl MR capsule formulation will be administered orally in a single dose
Study: NCT01418352
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole tablets once weekly for 8 weeks.
Study: NCT01637675
Drug: 20 mg sildenafil citrate by mouth
Normalized name: sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks
Study: NCT01637675
Drug: sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection will also be permitted if necessary) 250ml iv drip once a day for 8 weeks,as well as 20mg sildenafil citrate tablets by mouth three times a day for the same duration of treatment
Study: NCT00407459
Drug: Bevacizumab, Pemetrexed, Carboplatin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Bevacizumab: 15 mg/kg intravenous infusion over 30 to 90 minutes, following chemotherapy, on Day 1 every 3 weeks~* Pemetrexed: 500 mg/m2 intravenous infusion over 10 minutes on Day 1 every 3 weeks~* Carboplatin: AUC 5 intravenous infusion over 1 hour on Day 1 every 3 weeks
Study: NCT06568133
Drug: UIC201603 and co-administration of UIC201603 and UIC201604
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * UIC201603 2 Caps/day for 7 days~* Wash out 7 days~* UIC201603 2 Caps/day + UIC201604 1 Tabs/day for 7 days
Study: NCT06568133
Drug: UIC201604 and co-administration of UIC201603 and UIC201604
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * UIC201604 1 Tabs/day for 7 days~* Wash out 7 days~* UIC201603 2 Caps/day + UIC201604 1 Tabs/day for 7 daysadministration of UIC201603 and UIC201604
Study: NCT03468543
Drug: Memantine Hydrochloride MR Prototype Capsule Formulation B
Normalized name: Memantine Hydrochloride
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Memantine HCl MR capsule formulation will be administered orally in a single dose
Study: NCT00406432
Drug: Paroxetine Controlled Release Tablet
Normalized name: paroxetine Extended Release Oral Tablet
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible subjects will receive paroxetine controlled release tablet with dose of 25 milligrams.
Study: NCT03468543
Drug: Memantine Hydrochloride MR Prototype Capsule Formulation C
Normalized name: Memantine Hydrochloride
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Memantine HCl MR capsule formulation will be administered orally in a single dose
Study: NCT03468543
Drug: Memantine Hydrochloride MR Prototype Capsule Formulation D
Normalized name: Memantine Hydrochloride
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Memantine HCl MR capsule formulation will be administered orally in a single dose
Study: NCT03468543
Drug: Memantine Hydrochloride MR Prototype Capsule Formulation E
Normalized name: Memantine Hydrochloride
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Memantine HCl MR capsule formulation will be administered orally in a single dose
Study: NCT04514770
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rupture of membrane early and late
Study: NCT03236493
Drug: PF-06700841
Normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06700841 will be administered as tablet
Study: NCT00947245
Drug: BMS-791325
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, Oral, 300 mg, Single Dose, One day
Study: NCT00947245
Drug: BMS-791325
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, Oral, 900 mg, Single Dose, One day
Study: NCT00947245
Drug: BMS-791325
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, Oral, ≤1200 mg, Single Dose, One day
Study: NCT00947245
Drug: BMS-791325
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, Oral, 300 mg, Every 12 hours, 14 days
Study: NCT00947245
Drug: BMS-791325
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, Oral, 900 mg, once daily 14 days
Study: NCT00947245
Drug: BMS-791325
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, Oral, ≤1200 mg, Every 12 hours or once daily, 14 days
Study: NCT03603431
Drug: MRG-110
Normalized name: MRG-003
DrugBank: MRG-003 (DB17407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending doses of MRG-110
Study: NCT03603431
Drug: MRG-110
Normalized name: MRG-003
DrugBank: MRG-003 (DB17407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses of MRG-110
Study: NCT00765466
Drug: AVR118
Normalized name: AVR118
DrugBank: AVR118 (DB04979)
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily doses of 4.0 mL AVR118 subcutaneously
Study: NCT00293826
Drug: AMG 108
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg via SC (subcutaneous) injection every 4 weeks
Study: NCT00293826
Drug: AMG 108
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg via SC (subcutaneous) injection every 4 weeks
Study: NCT00293826
Drug: AMG 108
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125mg via SC (subcutaneous) injection every 4 weeks
Study: NCT04014101
Drug: SHR-1210
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
Study: NCT00437970
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg of Pioglitazone taken orally twice a day
Study: NCT00437970
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg of Metformin taken orally twice a day
Study: NCT04008043
Drug: Vicodin
Normalized name: Vicodin
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to taking one tablet of vicodin for pain every 4-6 hours up to 8 tablets, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
Study: NCT04008043
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In addition to taking one tablet of dexamethasone for pain beginning the day before surgery and on the day of surgery, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
Study: NCT02515812
Drug: I-123-MIBG
Normalized name: IOBENGUANE SULFATE I-123 25 mCi INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [i 123 MIBG meta iodobenzylguanidine]
DrugBank: Guanidine (DB00536)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04014101
Drug: apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib is a selective VEGFR2 inhibitor.
Study: NCT00921804
Drug: AZD 8529
Normalized name: aspirin / hydrocodone bitartrate Oral Tablet [Azdone]
DrugBank: AZD8529 (DB16073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg oral daily capsule administered as a single dose in the morning for 28 days
Study: NCT00921804
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4mg (2mg on Day 1) oral daily capsule administered as a single dose in the evening for 28 days
Study: NCT00921804
Drug: Placebo to match AZD8529
DrugBank: AZD8529 (DB16073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match AZD8529 administered as a daily capsule in the morning for 28 days during the treatment period and also during the 3-7 day washout or run-in period
Study: NCT00921804
Drug: Placebo to match risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo to match risperidone administered as a daily capsule in the evening for 28 days during the treatment period and also during the 3-7 day washout or run-in period
Study: NCT03798522
Drug: Nalbuphine
Normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in nalbuphine for analgesia after GA
Study: NCT02571725
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib starts concomitantly with the first dose of Tremelimumab